A Prospective, Double-Blind, Placebo-Controlled Study of Suramin in Subjects with Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI

Grants and Contracts Details

StatusFinished
Effective start/end date4/30/212/14/24

Funding

  • Rediscovery Life Sciences AKI LLC: $43,133.00